Institutional Investors Hate on Charming Shoppes Inc Falls

Coherus BioSciences, Inc. (NASDAQ:CHRS) Logo

Sentiment for Charming Shoppes Inc (NASDAQ:CHRS)

Charming Shoppes Inc (NASDAQ:CHRS) institutional sentiment decreased to 1.11 in Q3 2018. Its down -1.17, from 2.28 in 2018Q2. The ratio has dropped, as 51 investment professionals started new and increased equity positions, while 46 reduced and sold their equity positions in Charming Shoppes Inc. The investment professionals in our partner’s database now own: 59.61 million shares, up from 57.78 million shares in 2018Q2. Also, the number of investment professionals holding Charming Shoppes Inc in their top 10 equity positions increased from 0 to 1 for an increase of 1. Sold All: 14 Reduced: 32 Increased: 40 New Position: 11.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $834.67 million. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

The stock decreased 0.81% or $0.1 during the last trading session, reaching $12.27. About 142,758 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has risen 17.75% since January 14, 2018 and is uptrending. It has outperformed by 17.75% the S&P500.

Analysts await Coherus BioSciences, Inc. (NASDAQ:CHRS) to report earnings on March, 14. They expect $-0.82 EPS, up 2.38 % or $0.02 from last year’s $-0.84 per share. After $-0.87 actual EPS reported by Coherus BioSciences, Inc. for the previous quarter, Wall Street now forecasts -5.75 % EPS growth.

Acuta Capital Partners Llc holds 2.08% of its portfolio in Coherus BioSciences, Inc. for 353,500 shares. Pier Capital Llc owns 636,744 shares or 1.33% of their US portfolio. Moreover, Hound Partners Llc has 0.77% invested in the company for 2.01 million shares. The Singapore-based Temasek Holdings (Private) Ltd has invested 0.63% in the stock. Sivik Global Healthcare Llc, a Connecticut-based fund reported 99,101 shares.

More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: which released: “Your Daily Pharma Scoop: Coherus Biosciences Surges, Savara’s Aironite Flops, Biogen’s SPINRAZA – Seeking Alpha” on March 13, 2018, also with their article: “Coherus BioSciences Management to Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco – GlobeNewswire” published on April 02, 2018, published: “Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings, IPOs (Oct. 28-Nov. 3) – Benzinga” on October 27, 2018. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: and their article: “Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate) – GlobeNewswire” published on May 03, 2018 as well as‘s news article titled: “Key events next week – healthcare – Seeking Alpha” with publication date: October 26, 2018.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.